Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26 USD | +0.19% | -0.31% | +95.49% |
May. 02 | Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target | MT |
Evolution of the average Target Price on Dyne Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Dyne Therapeutics, Inc.
Morgan Stanley | |
Chardan Research | |
Stifel Nicolaus | |
Piper Sandler | |
Oppenheimer | |
HC Wainwright | |
Raymond James | |
Guggenheim | |
JPMorgan Chase |
EPS Revisions
- Stock Market
- Equities
- DYN Stock
- Consensus Dyne Therapeutics, Inc.